Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   31/05/2024
135,41 USD (-0,91%)
(-0,91%)   31/05/2024

29 mei 2024 · Neurocrine Biosciences to Participate at Investor Conferences in June · Persbericht

28 mei 2024 · Neurocrine Biosciences Announces CEO Succession Plan · Persbericht

28 mei 2024 · Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 · Persbericht

21 mei 2024 · Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules · Persbericht

14 mei 2024 · Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 · Persbericht

9 mei 2024 · Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 · Persbericht

9 mei 2024 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults · Persbericht

8 mei 2024 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults · Persbericht

7 mei 2024 · Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference · Persbericht

7 mei 2024 · Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 · Persbericht

6 mei 2024 · Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring · Persbericht

3 mei 2024 · Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 · Persbericht

1 mei 2024 · Neurocrine Biosciences Reports First Quarter 2024 Financial Results · Persbericht

30 april 2024 · Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules · Persbericht

24 april 2024 · Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community · Persbericht

23 april 2024 · Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder · Persbericht

10 april 2024 · Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results · Persbericht

3 april 2024 · Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder · Persbericht

28 maart 2024 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults · Persbericht

11 maart 2024 · Neurocrine Biosciences to Participate at Virtual Investor Conferences in March · Persbericht

Mijn selecties